



Annual Report 2025



Contents

IFPA in brief	3
Message from the Executive Director & Board	4
The Organization	5
IFPA Board	6
IFPA Secretariat	7
IFPA Members	8
Our Partners	12
Progress Toward Strategic Goals	14
Ensure Global Representation	16
Lead Global Advocacy	17
Strengthen Member Capacity	19
Share Knowledge	20
Unite Stakeholders	22
Flagship Programs in 2025	23
IFPA Forum	24
IFPA Conference	25
World Psoriasis Day	26
IFPA Accelerator Program	27
Projects in 2025	28
IFPA Coalition	29
IFPA Ambassadors	30
Breaking Barriers	32
Beyond The Flare	33
Global Psoriasis Atlas	34
IFPA Funds	35
Industry Partners	36



Vision

A future where all people living with psoriatic disease enjoy good health and well-being, free from stigma and preventable disability and comorbidities.



Mission

Unite, strengthen, and lead the global psoriatic community to improve the lives of all people affected by psoriatic disease.

IFPA in brief



IFPA, the International Federation of Psoriasis Associations, was founded in 1971 and is based in Stockholm, Sweden. It is the global organization dedicated to advocating for everyone living with and affected by psoriatic disease. IFPA's members are national and regional patient associations representing over 100 million people worldwide.

Disease prevalence

According to the Global Psoriasis Atlas, an estimated 43 million people have psoriasis based on diagnoses from reporting physicians/dermatologists. The physician-diagnosed prevalence is based on data from 41 countries where studies are available. Based on self-reported cases from individuals, an estimated 102 million people have psoriasis.


The figures highlight an important reality: many people with psoriatic disease remain undiagnosed or are unable to access appropriate care, and the global burden of psoriatic disease is likely higher than what existing studies can capture. These insights underscore the importance of continued efforts to improve awareness, diagnosis, and access to treatment worldwide.

Purpose of the Federation

IFPA is the global voice dedicated to advancing psoriatic disease policy. IFPA is a trusted convener of psoriatic disease stakeholders across sectors and geographies, partnering to strengthen national and regional capacity and leadership. IFPA works with others to generate and share evidence, informing change that can address unmet needs for people living with psoriatic disease.

- **Legitimacy to represent people living with psoriatic disease:** IFPA is the only organization that brings a unified, worldwide voice from people living with psoriatic disease into the global agenda.
- **History and track record in the psoriatic community:** IFPA has been unifying the psoriatic community for over 50 years and has a proven track record of elevating psoriatic disease on the global agenda.
- **Independence and integrity:** IFPA's decisions are driven exclusively by the needs of people living with psoriatic disease.

Strategic goals



Message from the Executive Director & Board



Frida Dunger
Executive Director, IFPA



Ingvar Ágúst Ingvarsson
President, IFPA

When we think of all that we've accomplished together in the past year, we are filled with gratitude and pride. Through the dedication of our members, partners, and supporters, we've made remarkable strides in raising awareness of psoriatic disease and advocating for millions living with it around the world.

We've organized the IFPA Forum Americas, and together with our members and regional and global stakeholders, we've developed a roadmap for tackling psoriasis in Americas.

We've brought psoriasis into the debate at the UN General Assembly, where we closely followed the development related to the declaration on noncommunicable diseases and mental health. And finally, we've mobilized the global community during the World Psoriasis Day campaign.

Throughout the year, our team and ambassadors have raised psoriasis awareness during various international conferences and gatherings.

We remain steadfast in our goal: people with lived experience of psoriatic disease should be seen

as experts, and their voices should be reflected in health policies around the world. We will continue working hard to make this happen.

Thanks to the support and coordinated efforts from IFPA's members, partners, and other stakeholders across the community, a growing number of experts and decision-makers acknowledge psoriatic disease as a serious systemic condition that deserves attention, care, and inclusion in health policies. This mindset shift brings us closer to our vision: a world where people with psoriatic disease have access to the care and support they need – and where they can live full lives, free from stigma and discrimination.

As we move on into 2026, we are excited for the many new opportunities to push advocacy forward, raise awareness, and create meaningful impact.

With gratitude and optimism,

Frida and Ingvar

THE ORGANIZATION



IFPA Board



Ingvar Ágúst Ingvarsson
President



Helen Crawford
Vice President



Sofia Lovi Ramasamy
Secretary



Josef de Guzman
Treasurer



Silvia Fernandez Barrio
Board Member



Masanori Okuse
Board Member



Jaime Melancia
Board Member

IFPA Secretariat



Frida Dunger
Executive Director



Elisa Martini
Policy and Advocacy Manager



Sicily Mburu, M.D.
Scientific Officer



Janina Kostiukaite
Strategic Events and Projects Lead



Ida Mourujärvi
Finance and Administration Manager



Camille Lancelot
Community Manager



Raquel Vaz
Scientific Project Lead



Elena Krivovyaz
Communications Lead



Carola Pilarz
Design and Social Media
Communicator




Nichlas Mattsson
Accounting Administration Officer



Emma Kristensson Bennwik
Policy and Advocacy Lead

IFPA members



Africa

Regional Organization

PSORAFRICA

Ghana

Psoriasis Ghana

Kenya

Psoriasis Association of Kenya

Rwanda


Rwanda Psoriasis and Psoriatic Arthritis Organization

South Africa

South African Psoriasis Association

Americas


Latinapso	Latin American Psoriasis Network
Argentina	Asociación Civil para el Enfermo de Psoriasis
Brazil	Instituto Espaço de Vida Psoríase Brasil
Canada	Canadian Association of Psoriasis Patients; Canadian Psoriasis Network; Canadian Spondylitis Association
Colombia	Fundapso-Colombia
Dominican Republic	Fundación de Apoyo a Pacientes con Psoriasis
El Salvador	Asociación Psoriasis Nueva Vida El Salvador
Honduras	Fundación Psoriasis Honduras
Mexico	Unidos Contra la Psoriasis A.C.
Panama	Fundación Psoriasis de Panama
Peru	Asociación de Psoriasis y Arthritis Psoriásica - Perú
Puerto Rico	Asociación Puertorriqueña de Ayuda al Paciente de Psoriasis
United States	National Psoriasis Foundation
Uruguay	Asociación Psoriasis Uruguay



Europe

Regional Organization	EUROPSO
Austria	Pso-Austria Verein und Selbsthilfegruppe der PsoriatikerInnen in Österreich
Bulgaria	Асоциация на хората с псориазис и псориатични усложнения
Croatia	Društvo psorijatičara Hrvatske
Czech Republic	Spolek psoriatiků a atopických ekzematiků
Denmark	Psoriasisforeningen
Estonia	Eesti Psoriaasiliit
Finland	Psoriasisliitto
France	France Psoriasis
Georgia	Psoriasis Association of Georgia; საქართველოს ფსორიაზით დაავადებულ პაციენტთა ასოციაცია
Germany	Deutscher Psoriasis Bund
Greece	Epidermia
Hungary	Association of Hungarian Psoriasis Clubs
Iceland	Samtök Psoriasis og Exemsjúklinga

Ireland	Irish Skin Foundation
Israel	Israel Psoriasis Association
Italy	Associazione Psoriasici Italiani Amici della Fondazione Corazza
Montenegro	Association for helping people with rheumatic diseases Montenegro
The Netherlands	Psoriasispatiënten Nederland
Norway	Psoriasis- og eksemforbundet
Portugal	Associação Portuguesa da Psoríase
Romania	Asociația Pacienților cu Afecțiuni Autoimune
Russia	Association “Way to Health”
Serbia	Pacijenti protiv psorijaze 3P
Slovakia	Spolocnosť Psoriatikov a Atopikov SR
Slovenia	Društvo Psoriatikov Slovenije
Spain	Acción Psoriasis
Sweden	Psoriasisförbundet
Switzerland	Schweizerische Psoriasis und Vitiligo Gesellschaft
Turkey	Türkiye Sedef Hastalan Dayanışma Derneği
United Kingdom	The Psoriasis and Psoriatic Arthritis Alliance



South-East Asia

Regional Organization	PSORASIA
Bangladesh	Psoriasis Awareness Club Bangladesh
Indonesia	Yayasan Peduli Psoriasis Indonesia
Sri Lanka	SkinSriLanka

Western Pacific

Australia	Psoriasis Australia Inc.
China	银屑病病友互助网 (Mutual Assistance of Psoriasis Patients) 中国慢性皮肤病关爱公益基金 (China Chronic Skin Disease Fund)
Hong Kong	香港银屑病病友會 (Hong Kong Psoriasis Patients Association)
Japan	Japan Psoriasis Association
Malaysia	Persatuan Psoriasis Malaysia
Philippines	Psoriasis Philippines
Singapore	The Psoriasis Association of Singapore
South Korea	대한건선협회 (Korea Psoriasis Association)
Taiwan	台灣乾癬協會 (Psoriasis Association Taiwan)
Vietnam	HỘI VẢY NẾN VIỆT NAM (PsorViet)

Civil and Medical Society Partners



Industry Partners



77 SIDE EVENT HIGHLIGHTS

A DECADE OF ACTION SINCE THE WORLD HEALTH ASSEMBLY RESOLUTION ON PSORIASIS – WHAT'S NEXT?

In 2014, member states of the World Health Organization (WHO) adopted Resolution WHA 67.13, which recognized psoriasis as a serious non-communicable disease. A decade later, the International Federation of Psoriasis Associations (IFPA), the International Psoriasis Council (IPC), and the International League of Dermatological Societies (ILDS) gathered close to 50 contributors in a hall given during the 77th World Health Assembly in Geneva.

The purpose was to celebrate the significant achievements made since the adoption of WHO Resolution 67.13 and to discuss the next steps in advocating for and improving care for people with psoriasis disease.

This report outlines the actions taken and progress made since the adoption of WHO Resolution 67.13 and to discuss the next steps in advocating for and improving care for people with psoriasis disease.



Global report on PSORIASIS

World Health Organization




Psoriatic Disease and Comorbidities

GLOBAL LEADER IN FIGHT PSORIATIC DISEASE

IFPA



PROGRESS TOWARD STRATEGIC GOALS



Goals

- **Ensure global representation:**
Boost the voices of everyone living with psoriatic disease, everywhere.
- **Lead global advocacy:**
Fight for the interests of people affected by psoriatic disease.
Demand representation on global health and development agendas.
- **Strengthen member capacity:**
Strengthen IFPA members.
Raise national support for people living with psoriatic disease.
- **Share knowledge:**
Close the gap between knowledge and action.
Enable breakthroughs for people living with psoriatic disease.
- **Unite stakeholders:**
Build alliances.
Transform global, regional, and national collaboration.

These strategic goals are interrelated and equally important.
They are further broken down into different activities with performance indicators set for 2030.



ENSURE GLOBAL REPRESENTATION

As a global federation, IFPA is committed to representing everyone living with psoriasis and psoriatic arthritis, as well as their families and communities.

We aim to empower and strengthen our member movement through sustainable growth, ensuring lasting impact worldwide. United, we amplify the voices of everyone living with psoriatic disease, across the globe.

In 2025, IFPA welcomed two new member organizations, from Honduras and Rwanda. We also witnessed the birth of a regional patient organization, PsorAfrica. As of December 31, IFPA had 64 national member organizations in 61 countries, plus three regional member organizations.

64

national members

61

countries

3

regional members

PsorAfrica site visit

In February 2025, IFPA organized a visit for African members and prospects in Kigali, Rwanda. During the meeting, the formation of the regional organization PsorAfrica was announced and local priorities for the region were discussed.

Participants met with local dermatologists and a representative from the Ministry of Health, fostering valuable dialogue on psoriasis care in Africa. Additionally, training sessions were held on communications and advocacy to support effective regional engagement.



LEAD GLOBAL ADVOCACY

2025 was a key year for global health and for our community. The United Nations put noncommunicable diseases (NCDs) and mental health high on the agenda, with high-level discussions at the General Assembly and a new political declaration on NCDs to be considered.

In keeping with these developments, IFPA stepped up its global advocacy, working to ensure that psoriasis was included in the conversation.

Throughout 2025, IFPA focused on the link between psoriatic disease and comorbidities, highlighting the disease's complexity and its impact on the whole body, mental health, and all aspects of life.

IFPA at WHA78

In May, IFPA attended the World Health Assembly (WHA), the annual week-long event where health leaders from countries around the globe gather in Geneva to make decisions for the World Health Organization (WHO).

During WHA week, IFPA has an intense schedule of meetings, side events, and roundtable discussions. IFPA was paying special attention to four areas:

- Skin diseases as a global public health priority
- Rare diseases as a global health priority for equity and inclusion
- The changing landscape of WHO funding
- Mobilization ahead of the UN High-Level Meeting in September and the important declaration regarding NCDs and mental health.



IFPA at UNGA80

During the 80th United Nations General Assembly in September, IFPA was present in New York to attend the High-Level Meeting on the prevention and control of noncommunicable diseases and the promotion of mental health and well-being, and to follow the process of adopting the declaration on NCDs.

IFPA's advocacy team had collaborated actively with a large group of other civil society and global health stakeholders to review drafts of the NCD declaration and ensure that the needs of those living with psoriasis were considered and included in the document.

To ensure that psoriasis remained present in the global health discussions at the UN, IFPA organized an event on the sidelines of the General Assembly. Entitled "Psoriatic disease and NCDs: putting lived experience at the heart of policy," it highlighted the importance of including the lived experiences of people with NCDs like psoriatic disease when developing health policies.

The event attracted a diverse audience of civil society organizations, international organizations, and policymakers, both in-person and online. IFPA Ambassador Kate Reynolds, IFPA's Frida Dunger and Devex's Kate Warren discussed how psoriatic disease is connected with other noncommunicable diseases, such as depression, diabetes, and more



– and why patient voices must be at the center of health policy.

Devex captured this important conversation in a follow-up article, exploring how firsthand experiences of psoriatic disease can – and should – shape NCD policies and guide healthcare systems.



Read the event report:



Member Meeting in Bogotá

In 2025, IFPA continued to strengthen the capacity of its global network by bringing members together, building skills, and enabling collaboration and exchange of ideas.

The IFPA Member Meeting in Bogotá gathered 70 patient advocates and stakeholders from around the world for a full day of discussion and training. From digital tools to national policy influence, organizations worldwide are driving change – Argentina, Colombia, Denmark, Ecuador, El Salvador, Estonia, France, Malaysia, Spain, and Uruguay showcased innovative initiatives improving patient access, education, and awareness. Key themes included collaboration with healthcare professionals, treatment guidelines, diversity, funding, and reaching underserved communities.

Throughout the year, IFPA supported its members continuously with tools and structured dialogue. The IFPA Member Portal provided access to research, training, and shared resources, while regular “Community Corner” discussions enabled members to exchange insights on vital issues.

Together, such efforts help build a more connected and capable movement, ready to drive impact at both national and global levels. IFPA collected feedback through its annual member survey and individual calls, ensuring that members’ needs continue to shape its work.



Sharing knowledge is a core part of IFPA's strategy. While research on psoriatic disease continues to advance, this knowledge is not always reflected in clinical practice, health policy or public understanding of the disease. By staying up to date with research and translating it into accessible information, IFPA works to close the gap between knowledge and action in psoriatic disease.

Reports and science-based aware-raising content

In 2025, we created a report highlighting the association between cardiovascular disease and psoriatic disease.



To complement the in-depth reports that focused on each comorbidity, we also created a brochure with quick facts on the increased risk of developing comorbidities for people living with psoriatic disease.



The economic burden of psoriatic disease and its comorbidities

The project explores how timely and effective systemic treatment may reduce healthcare and societal costs by lowering the risk of comorbidities such as cardiovascular disease, diabetes, obesity and depression. The findings are being submitted to a peer-reviewed scientific journal, while white papers and infographics are also being developed to share the results with the broader audience.

Family planning and pregnancy

Working closely with three members/ambassadors, we created a checklist for women tailored to help

them navigate how to plan for having a family at all stages: pre-, during, and post-pregnancy. This checklist has been made for women to use as a journal, write down questions, concerns and care plans discussed with their doctor.



GoodCare for psoriatic arthritis

The GoodCare Project for psoriatic arthritis was launched in 2022 and is dedicated to empowering people living with psoriatic arthritis and healthcare providers with accessible tools and resources for improved PsA management. In 2025, IFPA launched Phase 3 of the project.

The materials developed are based on the treatment guidelines developed by GRAPPA.

The features of the new edition include:

- Launch of the The #1 Pocket Guide and illustration booklet in 9 languages
- Adding comorbidities and disease control in global PsA World
- Strengthening the role of ambassadors and members through new launched GoodCare fund
- Increasing participation in regional and global conferences, including the submission of poster

The key highlights were presented at ACR Convergence in November, 2025 by our ambassador, Kathleen Gallant.

Psoriasis and Beyond

This study project examines people's understanding of psoriatic disease and its impact on quality of life, the associated comorbidities; cardiovascular disease, diabetes, depression, anxiety, and psoriatic arthritis, and patient-doctor conversations.



Family Wellbeing project

In 2024, IFPA highlighted the important role of family, caregivers, and partners, also known as the Greater Patient, in the life of those affected by psoriatic disease. Despite several studies reporting a significant burden of psoriatic disease on the family, there is a general lack of understanding of the real impact on their lives.

We presented recommendations that could be applied locally and globally. These include: an awareness video showing some of the challenges and stigmatization by society, a webinar focusing on intimacy with Dr. Mitchell Tepper as a speaker. The project has also been presented as a poster at the IDEOM meeting in 2025 and received positive feedback on the importance of the topic.

Scientific collaboration & engagement in 2025

IFPA took part in dermatology and rheumatology congresses throughout the year, with a presence in both scientific sessions and exhibition areas. Across these platforms, IFPA brought forward the patient perspective, highlighting patient-centred care, family wellbeing, diversity, and the need for more holistic approaches to treatment.

AAD Annual Meeting, Orlando, March 7–11

The American Academy of Dermatology Annual Meeting gathered over 20,000 participants in Orlando. IFPA delegates, some members and ambassadors also took part in an advisory board and round table, sharing the patient perspective of living with psoriatic disease. At the conference, the IFPA delegates attended the IPC symposium, sessions in relevant fields, and engaged with experts.

EULAR, Barcelona, June 11–14

With around 14,000 delegates, the EULAR Congress provided a platform to present IFPA's work on psoriatic arthritis and resources developed on the topic, as well as interact with key opinion leaders, patient organizations and other delegates. New connections were built with the PARE group (People with Arthritis/Rheumatism in Europe). In addition, IFPA became a EULAR Scientific Affiliate.

IDEOM, Washington DC, June 27–28

The IDEOM annual meeting brought together a broad mix of stakeholders to define outcome measures for future clinical research. IFPA participated in discussions with clinicians, researchers, and patient partners.

APLAR, Fukuoka, September 3–7

At the APLAR Congress, attended by more than 2,500 participants, IFPA had a booth at the congress with two board members representing. The focus was on raising awareness of psoriatic arthritis and promoting upcoming IFPA Conference.

ESDR, Antwerp, September 11–13

At the ESDR meeting, attended by over 1,000 participants, IFPA had a booth, presenting our materials and campaigns.



IFPA at EADV Congress.

IFPA hosted a session in the main program titled “More Than Skin Deep: Addressing Psoriatic Disease and its Comorbidities,” chaired by Raquel Vaz and Sicily Mburu. The session attracted over 40 attendees, mainly researchers, and received positive feedback.

EADV, Paris, September 17–20

The EADV Congress gathered more than 20,000 delegates in Paris. IFPA co-hosted the joint patient booth, participated in coalition meetings, and organized a workshop titled “Talk That Heals: How Better Communication Drives Better Patient Outcomes,” co-chaired by IFPA Board Member Josef De Guzman. IFPA also contributed to the EADV Task Force, working to expand patient organization involvement at the congress.

ACR, Chicago, October 24–29

ACR Convergence brought together 13,000 participants from 98 countries. IFPA had a booth in the non-profit exhibition area, where we showcased our work on psoriatic arthritis. IFPA Ambassador Kathleen Gallant delivered a powerful presentation on lived experience and patient advocacy.

UNITE STAKEHOLDERS

IFPA works to build alliances within and across the psoriatic community. By doing so, we are transforming national, regional and global collaboration in ways that will ensure better lives for the millions living with psoriatic disease.

IFPA Forum Americas in Bogotá

In April 2025, stakeholders from the psoriatic community gathered in Bogotá for the IFPA Forum Americas, an event to promote regional action. The focus was on the Americas, but global representation gave the forum an international perspective.

15 speakers joined the psoriatic community to engage in panel discussions and interactive workshops on three themes:

- Access to care and early detection of psoriatic disease
- Psoriatic disease and non-communicable diseases
- Collaborative research in psoriatic disease

The forum set a clear course, and it is now up to patient associations, other stakeholders involved in



the cause, and people living with psoriatic disease – in every country – to implement the learnings from the event.

Annual gathering with policymakers in Geneva

In October 2025, IFPA organized its annual diplomatic lunch in Geneva. The event was titled “Towards Inclusive Health Policies: Addressing the Hidden Cost of Psoriatic Disease.”

Ambassador James Waweru, Kenya’s Deputy Permanent Representative to the United Nations in Geneva, attended the event, along with senior representatives from the World Health Organization,

Swiss Psoriasis and Vitiligo Organisation, and other stakeholders. The participants explored the link between psoriatic disease and other NCDs, looking at the impact on people living with psoriatic disease and on countries’ healthcare costs.

The result was a reaffirmed commitment to IFPA and to improving the quality of life for people living with psoriatic disease around the world.



FLAGSHIP PROGRAMS IN 2025



The IFPA Forum is a Flagship Program designed to put the needs of people living with psoriatic disease at the center of the policy discourse on the regional level. The third IFPA Forum was held in Bogota, Colombia, on April 4, 2025.

Ahead of the forum, several resources (a briefing book and theme briefs) were published on the IFPA website and translated into Spanish and Portuguese. Following the forum, later in the year, two new resources were published: a roadmap for action and an action playbook.

The IFPA **Roadmap** to Improved Care in the Americas provides a clear set of advocacy demands and practical strategies to guide efforts to improve psoriatic care in the Americas. These include actions for patient associations to raise awareness of the psoriatic disease burden and its impact, as well as calls for higher prioritization of the disease within national and regional policies. In this way, the roadmap lays out a path toward improved overall health and well-being for people living with psoriatic disease.

The IFPA Americas **Action Playbook** offers practical assistance to advocates and members of patient organizations in their efforts to raise awareness and recognition of psoriatic disease as a significant health issue that requires enhanced treatment and care.

The IFPA Forum Africa takes place in Nairobi, Kenya, May 7–9, 2026.



Read more about the IFPA Forum 





From Burden to Breakthrough: Bridging Science, Innovation and Patient-Centered Care

Since its inception in 2006, the World Psoriasis & Psoriatic Arthritis Conference (often referred to as the IFPA Conference) has been held every three years, providing a unique opportunity for scientists, researchers, healthcare professionals, educational leaders, patient experts, and advocates from around the world to come together and engage with the critical issues that affect people living with psoriatic disease. IFPA drives global scientific research through the conference, which has become a cornerstone event for medical and health professionals worldwide.

The IFPA Conference 2024 marked a significant milestone with the highest number of abstract submissions to date, reflecting groundbreaking research and advancements in the field. These

abstracts have been published in a special issue of the Acta DV journal and were distributed at multiple congresses during 2025.

The coming 8th edition of the conference will offer opportunities for delegates to exchange ideas, explore innovations, and deepen their understanding of psoriatic disease and its associated comorbidities – all through a patient-centered lens. The theme of the IFPA Conference 2027 will be “From Burden to Breakthrough: Bridging Science, Innovation and Patient-Centered Care.”

The conference will take place May 20–22 in Stockholm, Sweden, and will be led by three renowned professors:



Professor Jo Lambert



Professor Joel M. Gelfand



Professor Vinod Chandran



For more information, visit www.ifpaconference.com

Sustainable Development Goals



IFPA Goals



Psoriatic Disease and Comorbidities

World Psoriasis Day is an annual event dedicated to raising awareness and supporting people living with psoriatic disease. It is a unique and powerful opportunity for IFPA to take action, advocate for change, and demonstrate leadership among diverse stakeholder groups.

World Psoriasis Day brings attention to the severity of psoriatic disease and the everyday challenges faced by people living with it. It aims to:

- Spread information about psoriatic disease, refuting common misconceptions and increasing knowledge among people living with the condition
- Improve access to treatment by targeting health ministers, governments, and decision-makers
- Create a united platform to empower people living with psoriatic disease.

50+

Dedicated social media posts

250,000+

Views on social media

500+

Shares

IFPA uses World Psoriasis Day to mobilize engagement around a shared theme or goal.

World Psoriasis Day 2025 focused on the theme “Psoriatic Disease and Comorbidities.” The event was promoted under the hashtag #StopTheDominoEffect, highlighting the way psoriatic disease can trigger a domino effect of comorbidities like diabetes, cardiovascular disease, and depression.

The press release “World Psoriasis Day 2025: IFPA Calls to Stop the Domino Effect of Psoriasis” had 705,000 recorded views with a potential reach of two billion people.



Sustainable Development Goals



IFPA Goals



IFPA ACCELERATOR PROGRAM



The IFPA Accelerator Program is a training program that supports organizations in expanding their work and guides new advocates in establishing patient associations.

The program aims to:

- Accelerate IFPA's growth
- Leverage the skills and capacities of selected member associations in each region
- Strengthen regional alliances and facilitate the sharing of best practices within regions

In 2025, the program initiated a new training in the use of AI tools to develop and conduct real-world data surveys, analyze the data, and create infographics to display the results.



Learn more about the IFPA Accelerator Program


Sustainable Development Goals



IFPA Goals



PROJECTS IN 2025



Spearheading change

By collaborating across borders, sectors, and disease areas through the IFPA Coalition, IFPA generates support for implementing the recommendations outlined in the **Global Report on Psoriasis, developed by the World Health Organization (WHO) in 2016.**

In 2025, the IFPA Coalition counted 16 members from civil society, industry, and medical professional organizations. The coalition convened four times during the year: February (virtually), June (virtually), September (in person), and December (virtually).

During the meetings, members discussed the coalition's main advocacy initiatives:

- Resources, activities, and events around the theme of the year, psoriatic disease, and the disease's comorbidities
- The IFPA Forum (Americas and Africa), the resources developed for it, and its follow-up
- IFPA's activities and plans with WHO

Coalition members provided helpful input and contributed to discussions that will further amplify IFPA's advocacy work.

Learn more at www.ifpa-psy.com/projects/ifpa-coalition

16

Member organizations

4

Meetings



Sustainable Development Goals



IFPA Goals



Representing psoriatic disease in all its complexity

As people with lived experience of psoriasis, IFPA Ambassadors are experts in psoriatic disease. Their valuable input amplifies global efforts to improve the lives of people living with the condition.

In 2025, IFPA received a steady stream of requests to contribute patient testimonials, survey participants, and models for photo and video assets.


IFPA Ambassadors receive training in speech and advocacy. The aim is to create a skilled and united team, reliable and ready to speak up about psoriatic disease and its comorbidities in the global arena. The ambassadors' expert perspectives boost understanding of the diverse needs and experiences of people living with psoriatic disease, everywhere.

In 2025, IFPA Ambassadors:

- Received training in storytelling and advocacy
- Presented their stories at conferences and on panels
- Directed personal initiatives to address psoriatic disease and comorbidities
- Collaborated on World Psoriasis Day
- Attended the IFPA Forum
- Served on steering committees and participated in projects with civil society organizations and industry partners to raise awareness of patient priorities globally.




Learn more about the IFPA Ambassador Program



Sustainable Development Goals



IFPA Goals





Sustainable Development Goals



IFPA Goals



Addressing gaps and underrepresentation in clinical research

Factors such as ethnicity, geography, age, socioeconomic conditions, and comorbidities all shape how psoriatic disease manifests and how care is experienced.

Yet while psoriatic disease affects people of all backgrounds, clinical research does not reflect this diversity. Many communities remain underrepresented in clinical trials, with external stigma and discrimination deepening the inequalities. This limits understanding, slows innovation, and leaves people without equal access to effective care.

Breaking Barriers is a new global project from IFPA that explores why clinical participation gaps persist – and how they can be closed. Through collaboration among people living with psoriatic disease, researchers, healthcare professionals, and advocacy organizations it aims to identify and remove the social, cultural, and structural barriers that prevent inclusion in clinical research.

Breaking Barriers seeks to:

- Reduce stigma as a barrier to participation in clinical research
- Strengthen understanding of diversity within psoriatic disease
- Empower people living with psoriatic disease to take part in research
- Support healthcare professionals in promoting inclusive research practices
- Build equitable pathways to care and treatment access globally

The project focuses on:

- Developing accessible educational materials about clinical research and inclusion
- Publishing articles, fact sheets, and infographics that address stigma and equity in clinical trials
- Interviewing people living with psoriatic disease and healthcare professionals to gather lived-experience data
- Hosting webinars and awareness campaigns to highlight the importance of diversity in research
- Supporting IFPA members in adapting materials to their national and cultural contexts.




A podcast series on psoriatic disease

In 2025, IFPA launched a podcast series called **Beyond the Flare**. The series gets past the myths that surround psoriasis, exploring the real experience of people living with it and connecting with the diverse global community behind the disease.

The initiative is already generating meaningful engagement and elevating important conversations within our community. The series explores themes such as:

- The hidden burden of psoriasis
- Early intervention
- Comorbidities and long-term risks
- Multidisciplinary and holistic approaches to care
- Empowering patients to reclaim purpose and well-being

Three podcast episodes were released by the end of 2025, and four additional episodes will be produced in 2026. The podcast can be heard on both Acast and Spotify.



Learn more:



Worldwide epidemiology of psoriasis

The Global Psoriasis Atlas (GPA) is a collaboration between three leading international organizations in dermatology and psoriatic disease: IFPA, the International League of Dermatological Societies (ILDS), and the International Psoriasis Council (IPC). This long-term project collects open-access information about the global epidemiology of psoriasis.

In 2025, the third edition of the GPA website was launched on World Psoriasis Day. The new edition provides the most comprehensive look yet at psoriasis epidemiology worldwide, featuring:

- Data from **58** new prevalence-only studies
- Data from **4** new incidence-only studies
- Coverage across **41** countries, including **7** new ones
- Insights from **14** global regions
- New National Coordinators representing more than **40** countries
- An updated heat map on website front page, visualizing the prevalence of psoriasis around the world

In conjunction with the GPA project, IFPA has developed Psoriasis Issue Briefs to support member countries with data for systematic review. These provide information on the incidence of psoriasis and quantify global, regional, and country-specific estimates of its prevalence.

Learn more at www.globalpsoriasisatlas.org



“IFPA is honored to collaborate with ILDS and IPC on the Global Psoriasis Atlas (GPA) project. The GPA provides essential data on the global burden of psoriasis, mapping disease prevalence and its impact on quality of life. This evidence supports IFPA’s advocacy mission to improve the lives of individuals with psoriatic disease. By leveraging this data, IFPA can drive global recognition and action, ensuring that the unmet needs of people living with psoriasis are acknowledged and addressed.”

Ingvar Ágúst Ingvarsson, IFPA



Sustainable Development Goals



IFPA Goals



Dr. Hoseah Waweru Solidarity Fund

The IFPA Solidarity Fund was created to address the funding gap faced by many of IFPA’s members, by awarding grants to support advocacy, education, and awareness-raising in psoriatic disease. After the passing of IFPA’s President in 2024, the fund was renamed in his memory.

In 2025, the fund had one call for application. Of the 15 applying organizations, 8 were elected to share 22,000 EUR.

IFPA Start-Up Fund

The IFPA Start-Up Fund was created in 2023 to support individuals or groups who reside in a country where no patient association exists, and who have the ability to start one. It provides funding to specific Start-Up Projects whose purpose is to establish new patient associations.

In 2025, Start-Up Projects were initiated in Gambia and Paraguay.

Project Rare GPP Fund

The Project Rare GPP Fund is an opportunity for patient organizations to reach those in their region living with GPP (Generalized Pustular Psoriasis). National patient organizations are crucial to the fight against psoriatic disease, but they often lack resources to carry out desired initiatives. With the financial assistance from this fund, they can realize some of these projects.

During 2025, the fund had two calls for application, where applying organizations could share a total of 100,000 EUR. In the first round, closed in March, 3 out of 10 project applications were elected. In the second round, closed in September, 4 out of 10 project applications were elected.

Sustainable Development Goals



IFPA Goals



INDUSTRY PARTNERS

In 2025, IFPA received funding from AbbVie, Ammirall, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Johnson & Johnson, LEO Pharma, Novartis, Oruka, Pfizer, Takeda, and UCB. The contributions supported everything from the IFPA Partnership Program and Flagship Programs to various projects and initiatives within science and advocacy to improve the lives of all people affected by psoriatic disease. Project sponsors are displayed under the respective project description on IFPA's website.



IFPA in brief

IFPA is a non-profit organization uniting national and regional associations from around the globe.

At IFPA, we envision a world without suffering from psoriatic disease. To achieve this, we focus on empowering our members, improving living conditions for people living with psoriatic disease and raising awareness.

Through global coalitions, World Psoriasis Day campaigns, the IFPA Forum, and the World Psoriasis & Psoriatic Arthritis Conference, IFPA is redefining psoriatic disease as a key lens for stronger, more inclusive health systems.

Visit: ifpa-pso.com



© IFPA 2026
Published: May 2026
Version 1.0



IFPA

**GLOBAL LEADER IN FIGHTING
PSORIATIC DISEASE**

Slottsbacken 8
111 30 Stockholm

ifpa-pso.com

info@ifpa-pso.com

   [@psoriasisIFPA](https://www.instagram.com/psoriasisIFPA)